Morgan Stanley
ZNTL icon

Morgan Stanley’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Morgan Stanley’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.29M Buy
471,250
+121,043
+35% +$483K ﹤0.01% 4773
2026
Q1 		$819K Sell
350,207
-453,447
-56% -$1.17M ﹤0.01% 5247
2025
Q4 		$1.08M Sell
803,654
-604,175
-43% -$879K ﹤0.01% 5144
2025
Q3 		$2.13M Buy
1,407,829
+310,178
+28% +$465K ﹤0.01% 4736
2025
Q2 		$1.27M Buy
1,097,651
+3,693
+0.3% +$4.87K ﹤0.01% 4985
2025
Q1 		$1.74M Sell
1,093,958
-619,230
-36% -$1.34M ﹤0.01% 4693
2024
Q4 		$5.19M Buy
1,713,188
+101,621
+6% +$333K ﹤0.01% 3963
2024
Q3 		$5.93M Sell
1,611,567
-339,155
-17% -$1.23M ﹤0.01% 3840
2024
Q2 		$7.98M Buy
1,950,722
+913,313
+88% +$10.2M ﹤0.01% 3492
2024
Q1 		$16.3M Buy
1,037,409
+427,926
+70% +$5.89M ﹤0.01% 2913
2023
Q4 		$9.23M Buy
609,483
+63,863
+12% +$932K ﹤0.01% 3418
2023
Q3 		$10.9M Buy
545,620
+42,745
+9% +$1.08M ﹤0.01% 3043
2023
Q2 		$14.2M Buy
502,875
+231,611
+85% +$5.56M ﹤0.01% 2836
2023
Q1 		$4.67M Buy
271,264
+137,805
+103% +$2.79M ﹤0.01% 3837
2022
Q4 		$2.69M Buy
133,459
+36,065
+37% +$776K ﹤0.01% 4265
2022
Q3 		$2.11M Sell
97,394
-248,345
-72% -$6.79M ﹤0.01% 4386
2022
Q2 		$9.71M Buy
345,739
+167,894
+94% +$4.45M ﹤0.01% 3095
2022
Q1 		$8.21M Buy
177,845
+147,701
+490% +$7.97M ﹤0.01% 3141
2021
Q4 		$2.53M Sell
30,144
-18,087
-38% -$1.4M ﹤0.01% 4391
2021
Q3 		$3.21M Sell
48,231
-20,251
-30% -$1.17M ﹤0.01% 4160
2021
Q2 		$3.64M Buy
68,482
+15,413
+29% +$825K ﹤0.01% 4111
2021
Q1 		$2.3M Sell
53,069
-47,851
-47% -$2.06M ﹤0.01% 4141
2020
Q4 		$5.24M Buy
100,920
+93,346
+1,232% +$4.21M ﹤0.01% 3210
2020
Q3 		$248K Sell
7,574
-2,551
-25% -$89.3K ﹤0.01% 4996
2020
Q2 		$486K Buy
+10,125
New +$388K ﹤0.01% 4614

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Morgan Stanley's ZNTL Position: Q2 2026 in Review

Morgan Stanley increased its Zentalis Pharmaceuticals (ZNTL) stake by 35% in Q2 2026, buying an estimated $483K and bringing the position to 471,250 shares worth $2.29M. The position accounts for ﹤0.01% of the portfolio, ranked #4773.

Morgan Stanley first reported a position in ZNTL in Q2 2020 and has held it in 25 quarters since. The position peaked at $16.3M in Q1 2024. 114 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

  • Morgan Stanley held 471,250 shares of Zentalis Pharmaceuticals worth $2.29M as of Q2 2026.
  • Morgan Stanley bought 121,043 Zentalis Pharmaceuticals shares in Q2 2026, an estimated $483K.
  • Zentalis Pharmaceuticals made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #4773 holding.
  • Morgan Stanley first reported a position in Zentalis Pharmaceuticals in Q2 2020 and has held it in 25 quarters since.
  • Morgan Stanley's Zentalis Pharmaceuticals position peaked at $16.3M in Q1 2024.
  • 114 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.